New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:20 EDTEWEdwards Lifesciences reports positive data on Sapien 3 valve
Edwards Lifesciences announced that the first data on its most advanced commercially available transcatheter aortic heart valve, the Edwards SAPIEN 3 valve, were presented in a late-breaking clinical trial session at EuroPCR 2014 by John Webb, director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital, Vancouver, and professor of cardiology at the University of British Columbia. The presentation concluded that outcomes at 30 days were excellent. Transfemoral SAPIEN 3 implantation was associated with a very low mortality of 2.1%, a stroke rate of 1.0%, and very few access-site complications.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
10:13 EDTEWHigh option volume stocks
Subscribe for More Information
06:34 EDTEWEdwards Lifesciences price target raised to $120 from $95 at Piper Jaffray
Piper Jaffray raised its price target for Edwards Lifesciences shares to $120 saying recent Transcatheter Aortic Valve Replacement market momentum is likely to continue. The firm keeps an Overweight rating on the stock.
September 18, 2014
09:19 EDTEWGeneration Investment reports 5.2% passive stake in Edwards Lifesciences
September 16, 2014
07:27 EDTEWEdwards Lifesciences price target raised to $114 from $103 at Canaccord
Canaccord raised its price target on Edwards Lifesciences to $114 from $103 following positive updates on the SAPIEM franchise and on the heels of several positive trends and upside surprises across the businesses during the quarter. Canaccord maintains its Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use